Cardiovascular diseases, such as heart attack and stroke, remain the leading cause of death worldwide, although classical risk factors are being treated more and more extensively. Research shows that the residual risk can be addresses by immunomodulation. This promising therapeutic target goes in line with the "inflammatory hypothesis" of atherosclerosis and is supported by several clinical trials (e.g. CANTOS, COLCOT and LoDoCo).
Dr. med. Kai-Uwe Jarr is a physician-scientist at the Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital (Chief: Prof. Dr. med. Nobert Frey). With the financial support of the Corona Foundation, the research team led by Dr. med. Kai-Uwe Jarr will continue to investigate innovative immunotherapies customized for cardiovascular diseases to open up new avenues. In oncology, these new therapeutic approaches have already revolutionized the treatment and prognosis for many patients.
Scientific contact:
Dr. med. Kai-Uwe Jarr, Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, kai-uwe.jarr(at)med.uni-heidelberg.de, https://jarrlab.owlstown.net
